Çalışkan, SelahattinKeleş, Muzaffer OğuzÖztürk, Metin İshakKutluhan, Musab AliTok,Olgu EnisErcan, FerihaKaraman, Muhammet İhsan2019-05-132019-05-132017Çalışkan, S., Keleş, M. O., Öztürk, M. İ., Kutluhan, M, A., Tok O. E., Ercan, F., Karaman, M. İ. (2017). Effect of sildenafil citrate in testosterone induced benign prostate hyperplasia rat model. Turkish Journal of Urology, 43(4), 434-8.2149-3235https://doi.org/10.5152/tud.2017.23356https://hdl.handle.net/11491/1853Objective: Efficacy of treatments for benign prostate hyperplasia (BPH) is limited because the disease has complex etiopathogenesis. Recent studies have demonstrated the presence of phosphodiesterase-5 (PDE-5) receptors in prostate tissue. We investigated efficacy of sildenafil citrate in testosteron - induced BPH in rats. Material and methods: The rats were divided into three groups. Each groups had 7 rats. Group 1 was control group. Testosteron propionate 3 mg/kg/day was injected subcutaneously for two weeks in Group 2. The same procedure was done for Group 3 and sildenafil citrate was added to water at daily doses of 2 mg/kg for two weeks. The rats were euthanized with intraperitoneal pentobarbital. The body weights were measured and the prostates were removed. Results: The mean weights of rats were 288±31.93, 345±23.23 and 294±32.86 g in Groups 1, 2 and 3, respectively. The mean prostate weights of rats were 0.74±0.18, 1.3±0.13 and 0.72±0.24 g in Groups 1, 2, and 3, respectively. Group 2 had statistically significantly higher prostate weights than the other groups (p<0.01). Relative prostate weight is calculated with ratio of prostate weight to body weight. BPH group showed an increase in relative prostate weight compared with other groups with significant difference (p=0.036 and p=0.040). There was statistical difference for acinar area between Group 2 and the others, no significant difference of number of acini, interstitial space and epithelial thickness. Group 2 has more papillary projections per acini than the other groups. Conclusion: Favourable effect of sildenafil citrate on dimensions of prostate but not all on histological parameters was observed. We expect that PDE-5 inhibitors might be a treatment option for BPH patients if the studies support our findings in the future. © 2017 by Turkish Association of Urology.eninfo:eu-repo/semantics/openAccessHyperplasiaProstateSildenafil CitrateArticle43443443810.5152/tud.2017.23356N/AN/A